BAYOOMED
  • Portfolio
    • Solutions
      • Mobile Medical Apps
      • Connectivity
      • Cloud based Solutions
      • Desktop and Web Solutions
      • Artificial Intelligence
      • Cybersecurity
      • Agile Software Development
      • Verification and Validation
    • Product Launch
      • Digital Health Applications (DiGA)
      • BAYOOCARE
    • Support
      • Regulatory Support
      • Risk Management
      • Clinical Evaluation
      • Quality Management
      • Usability Engineering
      • Approval
      • Classification
      • Post-Market Surveillance
  • Medical Software
    • Product Development
      • Requirements Management
      • Software Architecture
      • Software Engineering
      • Embedded Software
      • Verification and Validation
  • About Us
    • About BAYOOMED
      • Team
      • Certification (ISO 13485 Certificate)
      • Medical Device Experts
    • About BAYOONET
      • BAYOOSOFT
      • BAYOOTEC
      • BAYOOCARE
    • Success Stories
  • News
  • Jobs and Career
  • Search
  • Menu

AI in medical devices – a regulatory perspective

The possible application scenarios of artificial intelligence in medical technology seem endless. The use of superintelligence in particular harbours as yet untapped potential, as well as risks.

While a weak AI is understood to be an intelligence that is only superior to humans in very specific areas, a superintelligence – equal to humans – can learn and make decisions.

But what do manufacturers have to consider when approving AI-based medical software? And how do the regulatory requirements of the European market differ from those in the USA?

The comparison shows:

In Europe, the requirements of Regulation (EU) 2017/745 for software products apply above all. This is because AI can be considered a sub-discipline of software from a technical perspective. According to Annex I No. 17 of the regulation, software must be designed to ensure repeatability, reliability and performance in accordance with its intended use.

The FDA, on the other hand, distinguishes between artificial intelligence and software-based medical devices. In addition, only “locked algorithms” that have a completed learning phase are approved in the USA.

While the FDA presented a concept in 2019 with the Total Product Lifecycle (TPLC) that is intended to enable AI-based medical software to continue learning, in the EU it remains questionable for the time being: How can artificial intelligence be used effectively and safely?

Would you like to learn more about the approval of AI-based medical software? Feel free to contact us!

Contact

News

  • Women at BAYOOMEDGrowing Femtech: How Apps like MyIUS effect a change20. December 2022 - 14:53
  • Banner der HIMSS 2022Meet us at HIMSS 2022 in Helsinki10. June 2022 - 18:29
  • Eine Frau und ein Mann sitzen mit dem Tablet und Notizblock in der HandBAYOOMED @TT SDC in Brussels10. May 2022 - 12:26
Your contact at BAYOOMED

Miriam Schulze
CEO
miriam.schulze@bayoo.net

Darmstadt
Europaplatz 5
64293 Darmstadt

Munich
Aidenbachstraße 54
81379 München

Berlin 
Mariendorfer Damm 1-3
12099 Berlin

Contact:

Phone: +49 (0) 6151 – 86 18 – 0
Fax: +49 (0) 6151 – 86 18 – 150

E-mail: info@bayoo.net
Support: support@bayoo.net
Jobs: jobs@bayoo.net
Press: presse@bayoo.net

© Copyright - BAYOOMED
  • Contact
  • BAYOONET AG
  • Data Protection Policy
  • Imprint
  • Kontakt
  • BAYOONET AG
2nd Virtual Edition MedtecLIVE & SUMMIT Cybersecurity requirements for network-enabled medical devices
Scroll to top